Barclays analyst Etzer Darout raised the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $234 from $225 and keeps an Overweight rating on the shares following the Q1 report. Jazz reported “strong financial updates, with all core drivers beating consensus,” the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JAZZ:
- Jazz Pharmaceuticals reports Q1 adjusted EPS $6.34, consensus $4.66
- Jazz Pharmaceuticals sees FY26 revenue $4.25B-$4.5B, consensus $4.45B
- JAZZ Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Jazz Pharmaceuticals’ sBLA for Ziihera combination in GEA accepted by FDA
- Jazz Pharmaceuticals price target raised to $225 from $224 at Barclays